Background Evidence from clinical trials in the past decade has consistently shown that
angiotensin-converting enzyme (ACE) inhibitors reduce morbidity and mortality in patients …

Background: While the use of angiotensin-converting enzyme (ACE) inhibitors for patients
with congestive heart failure (CHF) is supported by the results of clinical trials and expert …

Background Despite randomized controlled trials demonstrating mortality reduction, many
studies have documented persistent low rates of prescription of angiotensin-converting …

Background The benefit of angiotensin-converting enzyme (ACE) inhibitors on mortality in
heart failure has been proved in randomized controlled trials. Methods We prospectively …

The effectiveness of the different angiotensin-converting enzyme (ACE) inhibitors in the
treatment of patients with congestive heart failure (CHF) was compared by performing a …

Because they provide relief of symptoms and reduce mortality, angiotensin-converting
enzyme (ACE) inhibitors have become a highly recommended part of the pharmacologic …

Background. The extent to which age plays a role in the underutilization of angiotensin-
converting enzyme (ACE) inhibitors in heart failure patients has not been well studied …

Background: Angiotensin‐converting enzyme (ACE) inhibitors were underprescribed for
patients with congestive heart failure (CHF) treated in the community setting in the early …

Objective.—To evaluate the effect of angiotensin-converting enzyme (ACE) inhibitors on
mortality and morbidity in patients with symptomatic congestive heart failure. Data Sources …

Background We sought to describe the dosages of angiotensin-converting enzyme (ACE)
inhibitor prescribed to elderly patients with heart failure at hospital discharge, the factors …